Obstacles and options in the quest for drug candidates against vascular disease

Thrombosis and Haemostasis

Volumn 104, Issue 1, 2010, Pages 1-3

  Weber, Christian ^a,b  

^a UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^b MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

Atherosclerosis; Chemokines; Drug design

Indexed keywords

A 002; BIOLOGICAL PRODUCT; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; CHOLESTEROL ESTER TRANSFER PROTEIN INHIBITOR; CKEY 2; DARAPLADIP; GLITAZONE DERIVATIVE; MARAVIROC; MICRORNA; MIR 126; PHOSPHOLIPASE A2 INHIBITOR; PIOGLITAZONE; RIMONABANT; ROSIGLITAZONE; ROSUVASTATIN; TORCETRAPIB; UNCLASSIFIED DRUG; VICRIVIROC;

ABDOMINAL OBESITY; ATHEROSCLEROSIS; CLINICAL TRIAL; DIABETES MELLITUS; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; HEART FAILURE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MENTAL DISEASE; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; REPERFUSION INJURY; REVIEW; THROMBOSIS; TREATMENT OUTCOME; VASCULAR DISEASE;

AGING; ANIMALS; ANTICOAGULANTS; CARDIOVASCULAR DISEASES; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; DRUG DESIGN; HUMANS; METABOLIC DISEASES; QUINOLINES; RECEPTORS, CCR5; THIAZOLIDINEDIONES;

EID: 77954379634     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH10-04-0256     Document Type: Review

References (28)

1. Ridker PM, Danielson E, Fonseca FA, et al.; JUPITER Trial Study Group. Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet 2009; 373: 1175-1182.
2. Home PD, Pocock SJ, Beck-Nielsen H, et al.; RECORD Study Team. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet 2009; 373: 2125-2135.
3. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007; 356: 2457-2471. (Pubitemid 46919772)
4. Nissen SE. Setting the RECORD Straight. J Am Med Assoc 2010; 303: 1194-1195.
5. Lincoff AM, Wolski K, Nicholls SJ, et al. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. J Am Med Assoc 2007; 298: 1180-1188. (Pubitemid 47403104)
6. Nissen SE, Nicholls SJ, Wolski K, et al.; STRADIVARIUS Investigators. Effect of rimonabant on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease: the STRADIVARIUS randomized controlled trial. J Am Med Assoc 2008; 299: 1547-1560.
7. Nissen SE, Tardif JC, Nicholls SJ, et al.; ILLUSTRATE Investigators. Effect of torcetrapib on the progression of coronary atherosclerosis. N Engl J Med 2007; 356: 1304-1316.
8. Nicholls SJ, Tuzcu EM, Brennan DM, et al. Cholesteryl ester transfer protein inhibition, high-density lipoprotein raising, and progression of coronary atherosclerosis: insights from ILLUSTRATE (Investigation of Lipid Level Management Using Coronary Ultrasound to Assess Reduction of Atherosclerosis by CETP Inhibition and HDL Elevation). Circulation 2008; 118: 2506-2514.
9. BARI 2D Study Group, Frye RL, August P, et al.. A randomized trial of therapies for type 2 diabetes and coronary artery disease. N Engl J Med 2009; 360: 2503-2515.
10. Koenen RR, Weber C. Therapeutic targeting of chemokine interactions in atherosclerosis. Nat Rev Drug Discov 2010; 9: 141-153.
11. Braunersreuther V, Zernecke A, Arnaud C, et al. Ccr5 but not Ccr1 deficiency reduces development of diet-induced atherosclerosis in mice. Arterioscler Thromb Vasc Biol 2007; 27: 373-379.
12. Gulick RM, Lalezari J, Goodrich J, et al.; MOTIVATE Study Teams. Maraviroc for previously treated patients with R5 HIV-1 infection. N Engl J Med 2008; 359: 1429-1441.
13. Fätkenheuer G, Nelson M, Lazzarin A, et al.; MOTIVATE 1 and MOTIVATE 2 Study Teams. Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection. N Engl J Med 2008; 359: 1442-1455.
14. Kuritzkes DR. HIV-1 entry inhibitors: an overview. Curr Opin HIV AIDS 2009; 4: 82-87.
15. Hsue PY, Hunt PW, Schnell A, et al.. Role of viral replication, antiretroviral therapy, and immunodeficiency in HIV-associated atherosclerosis. AIDS 2009; 23: 1059-1067.
16. Weber C. Killing two birds with one stone: targeting chemokine receptors in atherosclerosis and HIV infection. Arterioscler Thromb Vasc Biol 2005; 25: 2448-2450.
17. Glass WG, McDermott DH, Lim JK, et al. CCR5 deficiency increases risk of symptomatic West Nile virus infection. J Exp Med 2006; 203: 35-40.
18. Koenen RR, von Hundelshausen P, Nesmelova IV, et al. Disrupting functional interactions between platelet chemokines inhibits atherosclerosis in hyperlipidemic mice. Nat Med 2009; 15: 97-103.
19. Weber C, Koenen RR. Fine-tuning leukocyte responses: towards a chemokine 'interactome'. Trends Immunol 2006; 27: 268-273.
20. von Hundelshausen P, Koenen RR, Sack M, et al. Heterophilic interactions of platelet factor 4 and RANTES promote monocyte arrest on endothelium. Blood 2005; 105: 924-930. (Pubitemid 40170856)
21. Damås JK, Waehre T, Yndestad A, et al. Stromal cell-derived factor-1alpha in unstable angina: potential antiinflammatory and matrix-stabilizing effects. Circulation 2002; 106: 36-42. (Pubitemid 34747439)
22. Zernecke A, Bot I, Djalali-Talab Y, et al. Protective role of CXC receptor 4/CXC ligand 12 unveils the importance of neutrophils in atherosclerosis. Circ Res 2008; 102: 209-217.
23. Schroeter MR, Humboldt T, Schäfer K, et al. Rosuvastatin reduces atherosclerotic lesions and promotes progenitor cell mobilisation and recruitment in apolipoprotein E knockout mice. Atherosclerosis 2009; 205: 63-73.
24. Zernecke A, Bidzhekov K, Noels H, et al. Delivery of microRNA-126 by apoptotic bodies induces CXCL12-dependent vascular protection. Sci Signal 2009; 2: ra81.
25. Stellos K, Bigalke B, Langer H, et al. Expression of stromal-cell-derived factor-1 on circulating platelets is increased in patients with acute coronary syndrome and correlates with the number of CD34+ progenitor cells. Eur Heart J 2009; 30: 584-593.
26. Corson MA. Phospholipase A2 inhibitors in atherosclerosis: the race is on. Lancet 2009; 373: 608-610.
27. Jennings LK. Mechanisms of platelet activation: need for new strategies to protect against platelet-mediated atherothrombosis. Thromb Haemost 2009; 102: 248-257.
28. Steffens S, Montecucco F, Mach F. The inflammatory response as a target to reduce myocardial ischaemia and reperfusion injury. Thromb Haemost 2009; 102: 240-247.